Essential Thrombocythemia (ET)
0
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
TakedaTOKYO, Japan
2 programsAnagrelide hydrochlorideN/A1 trial
Pediatric Disease Registry in Essential Thrombocythaemia (ET)N/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
TakedaAnagrelide hydrochloride
TakedaPediatric Disease Registry in Essential Thrombocythaemia (ET)
Clinical Trials (2)
Total enrollment: 107 patients across 2 trials
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Start: Jul 2011Est. completion: Sep 201347 patients
N/ACompleted
Pediatric Disease Registry in Essential Thrombocythaemia (ET)
Start: Sep 2010Est. completion: Mar 201660 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space